Clareo Health | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
A study to bank samples for future evaluation to identify genetic mutations and other biomarkers that predispose inflammatory bowel disease (IBD) patients to developing Hepatosplenic T-cell Lymphoma (HSTCL).
Age
1–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female who has received a single dose of HUMIRA prior to a confirmed diagnosis of HSTCL.
Confirmed diagnosis of CD or UC as documented by a Gastroenterologist or physician who diagnosed the CD or UC.
Confirmed diagnosis of HSTCL as determined by a biopsy performed on a specimen taken from the patient.
Patients 18 years old and older must voluntarily sign and date an IRB/EC approved Informed Consent Form. For patients younger than 18 years old, a parent or legal guardian is required to voluntarily sign and date an IRB/EC approved Informed Consent Form. Pediatric patients will be included in all discussions if possible, in order to obtain their assent.
You may not be if
Male or female who has not received at least a single dose of adalimumab prior to a confirmed diagnosis of HSTCL.
Unconfirmed diagnosis of HSTCL, CD or UC, respectively.
The patient or the patient's HCP is unwilling to participate in this study.
The parents or legal guardians (in the case of patients younger than 18 years of age), who are unable and/or unwilling to consent to the patient's participation in this study.
